uploads///Graph

International Markets: Abbott Laboratories’ Key Revenue Driver

By

Updated

Abbott’s revenue

In the first nine months of 2018, Abbott Laboratories (ABT) earned $8.08 billion from the US market, which was a YoY (year-over-year) rise of 15.5% and organic growth of 4.6%. Its international markets contributed $14.73 billion to revenues, which was a YoY rise of 15% and organic growth of 9.2%.

In the third quarter, it reported revenues of $2.71 billion from the US market, which was a YoY organic growth of 5.2% and reported growth of 17%. International markets accounted for $4.95 billion of revenues, which was a YoY organic growth of 9.2% and reported growth of 9.6%.

Year-to-date, international markets have accounted for a larger dollar portion of Abbott Laboratories’ revenues. Revenues from these markets are also growing YoY at a faster pace than the domestic US market.

Article continues below advertisement

Established Pharmaceuticals: Revenue trends

Abbott Laboratories’ Established Pharmaceuticals (or EPD) division is one of Abbott’s key drivers for its international markets. According to the company’s third-quarter earnings conference call, Abbott expects its EPD division to have mid-single-digit YoY growth in revenues for fiscal 2018.

In the first nine months of 2018, EPD reported revenues of $3.33 billion, which was a YoY organic growth of 8.3% and a reported growth of 6.1%. In the third quarter, it contributed revenues of $1.16 billion, which was a YoY organic growth of 5.9%.

However, EPD saw a 0.9% YoY decline in sales on a reported basis in the third quarter. According to Abbott’s press release on October 17, the decline was due to higher-than-normal purchasing in the Indian market related to channel restocking in the third quarter of 2017.

Abbott also said that EPD revenues were driven mainly by double-digit sales growth in key markets such as Russia and China. The company has had faster-than-market growth year-to-date for its generics business in several emerging markets, including China and India.

In the next part, let’s look at revenue trends for Abbott Laboratories’ Nutrition business.

Advertisement

More From Market Realist